Pioglitazone is a medication that is being tested to see if it can help protect the kidneys in people with a condition called ANCA-associated vasculitis. This condition can cause damage to the kidneys, and the trial is looking at whether adding pioglitazone to the usual treatment can reduce this damage. Pioglitazone is usually used to help control blood sugar levels in people with diabetes, but in this trial, it is being used to see if it can also help improve kidney function.

Glucocorticoids are a type of medication that helps reduce inflammation in the body. In this trial, they are part of the standard treatment for ANCA-associated vasculitis. These medications work by calming down the immune system, which can help prevent further damage to the kidneys caused by the disease.

Rituximab is a medication that is used to treat certain autoimmune diseases, including ANCA-associated vasculitis. It works by targeting specific cells in the immune system that are involved in causing inflammation and damage. In this trial, rituximab is part of the standard treatment plan, and researchers are studying how well it works alongside pioglitazone and glucocorticoids to protect the kidneys.

ANCA-associated vasculitis – ANCA-associated vasculitis is a group of diseases characterized by inflammation of small to medium-sized blood vessels, often affecting the kidneys, lungs, and other organs. The disease is associated with the presence of anti-neutrophil cytoplasmic antibodies (ANCA) in the blood. It typically begins with symptoms such as fatigue, fever, and weight loss, followed by more specific signs depending on the organs involved. As the disease progresses, it can lead to organ damage, particularly in the kidneys, causing issues like proteinuria and elevated serum creatinine levels. The inflammation can also cause damage to the respiratory system, leading to symptoms like coughing and shortness of breath. Over time, the disease can result in chronic damage to affected organs if not managed properly.